GO
| HSI1 | 25,042.71 | +291.93 | 202.73B |
| HSCEI1 | 8,339.63 | +114.23 | 56.78B |
| Back Zoom + Zoom - Block Traded | |
|
US Said to Unwind Curbs on Pharma Investment in CN, Retaining Most Drug Licensing Agreements
2026-09-21 16:01:18 The US is drafting rules targeting pharmaceutical companies' investments in China, and will likely preserve drugmakers' ability to enter into most drug licensing agreements with China, Reuters, citing sources, reported earlier. This implies the new rules will be looser than the restrictions sought by some lawmakers. The new rules drafted by the US Treasury Department may allow US pharmaceutical companies to invest in promising new drugs developed by Chinese companies, provided the drugs are unrelated to pathogens or biotechnology that could potentially be weaponized. The new rules could facilitate transactions worth billions of USD to help US companies replenish their drug development pipelines while providing funding to Chinese enterprises. ~ AASTOCKS Financial News Website: www.aastocks.com | |